Trastuzumab Resistance, a Potential Roadblock for Most Successful Therapy of Breast Cancer—An Updated Review of Underlying Mechanisms, Clinical Trials and Patents to Evade the Resistance

Trastuzumab is the first humanised monoclonal antibody (Mab) developed for breast cancer (BC) therapy. The high affinity of Trastuzumab Fab-domain binding to the human epidermal growth factor receptor 2 (HER2) receptor, with a K_d value of <1 nM, is also accompanied by Fc domain interactio...

Description complète

Détails bibliographiques

Auteurs principaux:	Gul Hasan, Soudipta Pramanik, Sandhya Singh, Pravin Gurav, Sudha Madhavi Penumaka, Sudheer Kumar, Debabrata Mandal
Format:	Artigo
Langue:	Inglês
Publié:	MDPI AG 2026-04-01
Collection:	Pharmaceutics
Sujets:	trastuzumab resistance HER2 receptor PI3K/AKT/mTOR pathway Mucin1 combination therapy patents & clinical trials
Accès en ligne:	https://www.mdpi.com/1999-4923/18/5/514
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!